Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy
Female or male aged 18 years and older at the time of enrollment.
Not pregnant and not nursing.
No active infection requiring parenteral antibiotic(s).
Patients have no intent to receive other anti-cancer therapy beyond daraxonrasib
No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients).
Patients who are able to understand and willing to sign the written informed consent form or patients who have impaired decision-making capacity but have a legally authorized representative who can consent on their behalf are eligible. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
You may not be if
Concurrent use of another investigational drug or device for the daraxonrasib-induced skin toxicity (i.e., outside of study treatment) during, or within 4 weeks of study treatment.
Patients receiving prednisone 10 mg/day or higher (or equivalent) at the time of randomization for indications other than daraxonrasib skin toxicity management.
Patients receiving tetracyclines, ivermectin or other systemic medication that could mask daraxonrasib rash development.
Pregnancy or planned pregnancy during the study period.
Documented allergy to oral ivermectin and / or minocycline
Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation.
